Abstracts Archive - Page 103 of 2607 - ACR Meeting Abstracts

Abstract Number: 0947 • ACR Convergence 2025
Mechanisms of anti-NMDAR antibody-mediated neuronal pathology and mitigation by angiotensin II signaling inhibition
Kaitlin Carroll¹, Mark Mizrachi¹, Sean Simmons², Bahtiyar Toz¹, Czeslawa Kowal³, Nazila Tehrani¹, Aida Zarfeshani¹, Nina Kello¹, Lara El Khoury⁴, Jeffrey Wingard¹, Rachel Weissman-Tsukamoto³, Joshua Levin², Bruce Volpe³ and Betty Diamond⁵, ¹Institute of Molecular Medicine, The Feinstein Institutes for Medical Research, Manhasset, NY, ²Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, ³Feinstein Institute of Molecular Medicine, Manhasset, NY, ⁴Zucker School of Medicine at Hofstra/Northwell Health, Great Neck, NY, ⁵The Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Cognitive impairment is a frequent manifestation of neuropsychiatric systemic lupus erythematosus, present in up to 80% of patients and leading to a diminished quality…
Abstract Number: 0962 • ACR Convergence 2025
Spatial Proteomics Analysis of the organization of tertiary lymphoid structures in Systemic Sclerosis Skin
Dennis Bleck¹, Karen Drechsel², Tim Filla³, Yi-Nan Li⁴, Andrea-Hermina Györfi⁵, Alexandru-Emil Matei⁶ and Jörg Distler⁷, ¹University Hospital Düsseldorf, Department of Rheumatology, Hiller Research Center, Düsseldorf, Nordrhein-Westfalen, Germany, ²University Hospital Düsseldorf, Department of Rheumatology, Hiller Research center, Düsseldorf, Nordrhein-Westfalen, Germany, ³Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, ⁴University Hospital of Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany, ⁵Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany, ⁶Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, ⁷University Hospital Duesseldorf and HHU, Duesseldorf, Germany
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune connective tissue disease and presents a significant medical challenge. It is characterized by fibrotic tissue remodeling, along…
Abstract Number: 0594 • ACR Convergence 2025
Patients with SLE Have an Increased Bisphenol A Methylation Score Linked to SLE Risk Genes and Immune Response Pathways
Holme Vestin¹, Nina Oparina¹, Maija-Leena Eloranta¹, Martina Frodlund², Iva Gunnarsson³, Chrisopher Sjöwall², Elisabet Svenungsson⁴, Lars Rönnblom¹, Juliana Imgenberg-Kreuz¹ and Dag Leonard¹, ¹Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection/Rheumatology, Linköping University, Linköping, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Stockholms Lan, Sweden
Background/Purpose: The pathogenesis of SLE involves genetic, environmental and epigenetic factors (1). Increased levels of Bisphenol A (BPA) have been observed in the urine of…
Abstract Number: 0064 • ACR Convergence 2025
Sclerostin from marrow adipogenic precursors is essential for bone and joint homeostasis in mice
Tailin He and Yifang Mei, Shenzhen Third People's Hospital, Shenzhen, China (People's Republic)
Background/Purpose: A novel mesenchymal subpopulation known as 'marrow adipogenic lineage precursors' (MALPs) has been identified, characterized by the expression of various adipocyte markers while lacking…
Abstract Number: 1102 • ACR Convergence 2025
Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.
Julia Barasch¹, Nilasha Ghosh², Deanna Jannat-Khah³, Kyle Ge⁴, Jeffrey Curtis⁵ and Anne R. Bass³, ¹NYP- Weill Cornell, New York, ²Hospital for Special Surgery, New York, NY, ³Hospital For Special Surgery, New York, NY, ⁴Hospital for Special Surgery, New York, ⁵Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: New onset inflammatory arthritis (IA) is reported in 6% of patients who receive immune checkpoint inhibitors (ICI). We previously developed an administrative claims-based algorithm…
Abstract Number: 1111 • ACR Convergence 2025
Checkpoint Inhibitor Induced Myocarditis with Myositis/Myasthenia Gravis Concurrence: An Observational Study
Maja Ivanovic¹, Daming Shao², Andrew Wang³, Craig Smuda² and Pankti Reid¹, ¹University of Chicago Medical Center, Chicago, IL, ²University of Chicago, Chicago, IL, ³University of Chicago Pritzker School of Medicine, Chicago, IL
Background/Purpose: Immune checkpoint inhibitor (ICI) induced myositis is the ICI rheumatic toxicity with the greatest case mortality rate, especially when associated with myocarditis and/or myasthenia…
Abstract Number: 1060 • ACR Convergence 2025
Demographic Risk Factors, Social Vulnerability Index, and Mortality in Patients with Systemic Lupus Erythematosus
Christine Kim¹, Katherine Mitchell², Changyong Feng¹ and Allen Anandarajah³, ¹University of Rochester, Rochester, NY, ²University of Rochester, Rochester, ³University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with multi-organ involvement that is characterized by relapses and remissions. Ethnicity, socioeconomic status, gender, age, education…
Abstract Number: 1084 • ACR Convergence 2025
Access to rheumatology care in patients with new diagnosis of polymyalgia rheumatica: analysis from a national inception cohort
Sebastian E Sattui¹, Orysya Soroka², Manuel Carpio Tumba³, Emily Holladay⁴, Fenglong Xie⁵, Sarah Mackie⁶, Jeffrey Curtis⁷, Robyn Domsic³ and Iris Navarro-Millan⁸, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Weill Cornell Medicine, New York, ³University of Pittsburgh, Pittsburgh, PA, ⁴University of Alabama at Birmingham, Edmond, OK, ⁵The University of Alabama at Birmingham, Birmingham, AL, ⁶University of Leeds, Leeds, United Kingdom, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Weill Cornell Medicine, Hospital for Special Surgery, Poughkeepsie, NY
Background/Purpose: Patients with polymyalgia rheumatica (PMR) are commonly diagnosed and cared for by non-rheumatology providers (i.e., primary care). Lack of access to specialty care can…
Abstract Number: 1071 • ACR Convergence 2025
Depression and Mental Health Service Gaps in Autoimmune Disease: Insights from a Simulated BRFSS Dataset
Malay Rathod¹, Shivani Modi², Veera Durga Vaishnavi Kurra³, Karan Yagnik⁴ and Doantrnag Du⁴, ¹Monmouth Medical Center, Ewing, NJ, ²Jefferson Einstein Montgomery Hospital, Ewign, NJ, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Monmouth Medical Center, Long Branch, NJ
Background/Purpose: Autoimmune diseases are complex conditions that may predispose individuals to an increased mental health burden, including depression. The immune system leads to inflammation in…
Abstract Number: 1089 • ACR Convergence 2025
Comparing the immunosuppressant burden in immune checkpoint inhibitor mediated inflammatory arthritis versus polymyalgia rheumatica: results from a prospective multicenter registry
Alice Tison¹, Deanna Jannat-Khah², Laura Cappelli³ and Anne R. Bass², ¹LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ²Hospital For Special Surgery, New York, NY, ³Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Inflammatory arthritis (IA)- and polymyalgia rheumatica (PMR)-like syndromes occur in about 6% of patients receiving an immune checkpoint inhibitor (ICI) and can worsen quality…
Abstract Number: 1027 • ACR Convergence 2025
GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients With Rheumatic and Musculoskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry
Nick McCormick¹, Jingyi Zhang², Emily Holladay², Fenglong Xie³ and Jeffrey Curtis⁴, ¹Auburn University, Auburn, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³The University of Alabama at Birmingham, Birmingham, AL, ⁴Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) such as semaglutide (SEM; GLP-1) and tirzepatide (TIR; GIP/GLP-1), were initially approved for type 2 diabetes management but…
Abstract Number: 1117 • ACR Convergence 2025
Inflammatory Arthritis after Hematopoietic Stem Cell Transplant: A Case Series and Literature Review
Scott Yeudall¹, Mark Levis², Jonathan Webster² and Laura Cappelli³, ¹The Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Hematopoietic stem cell transplant (HSCT) is a commonly employed treatment for hematologic malignancies including acute leukemias and lymphomas but can be complicated by graft-versus-host…
Abstract Number: 1066 • ACR Convergence 2025
Assessing Disparities in Outcomes and Processes of Care for Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
Julia Harris¹, Catherine Bingham², Sheetal Vora³, Jon Burnham⁴, Cagri Yildirim-Toruner⁵, Tzielan Lee⁶, Kerry Ferraro⁷, Erik Friedrichsen⁸, Katelyn Banschbach⁹, Michelle Batthish¹⁰, Danielle Fair¹¹, Mileka Gilbert¹², Beth Gottlieb¹³, Melissa Mannion¹⁴, Edward Oberle¹⁵, Nancy Pan¹⁶, Natalie Rosenwasser¹⁷, Mary Toth¹⁸, Jennifer Weiss¹⁹ and Esi Morgan¹⁷, ¹Children's Mercy Kansas City, Overland Park, KS, ²Penn State Children's Hospital, Hershey, PA, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Children's Hospital of Philadelphia, Bryn Mawr, PA, ⁵Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁶Stanford University School of Medicine, Palo Alto, CA, ⁷Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, ⁸Seattle Children's Hospital, Burien, WA, ⁹cincinnati Children's hospital, Villa Hills, KY, ¹⁰McMaster Children's Hospital, Hamilton, ON, Canada, ¹¹Medical College of Wisconsin/Children's Wisconsin, Wauwatosa, WI, ¹²Medical University of South Carolina, Charleston, SC, ¹³Cohen Children's Medical Center, Northwell Health, Lake Success, NY, ¹⁴University of Alabama at Birmingham, Birmingham, AL, ¹⁵Nationwide Children's Hospital, Columbus, OH, ¹⁶Hospital for Special Surgery, New York, NY, ¹⁷Seattle Children's Hospital, seattle, WA, ¹⁸Nemours Foundation, Orlando, FL, ¹⁹Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) has a mission to deliver exceptional and equitable health care to children with rheumatic diseases…
Abstract Number: 1077 • ACR Convergence 2025
Health literacy and work status in people with inflammatory arthritis: a cluster analysis in a national cohort
Mrinalini Dey¹, Sam Norton², Andrew Cope², MAYA BUCH³, Richard Osborne⁴, James Galloway² and Elena Nikiphorou², ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²King's College London, London, United Kingdom, ³UNIVERSITY OF MANCHESTER, MANCHESTER, United Kingdom, ⁴La Trobe University, Melbourne, Victoria, Australia
Background/Purpose: Work status and employment can be impacted in people with inflammatory arthritis (IA). We aimed to assess the association between health literacy and work…
Abstract Number: 1088 • ACR Convergence 2025
Unsupervised characterization of immune checkpoint inhibitor induced inflammatory arthritis using cluster and latent class analysis: result from a multicenter prospective registry
Alice Tison¹, Deanna Jannat-Khah², Laura Cappelli³ and Anne R. Bass², ¹LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ²Hospital For Special Surgery, New York, NY, ³Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: The broad use of immune checkpoint inhibitors (ICIs) in oncology has led to the emergence of ICI-induced inflammatory arthritis (ICI-IA). The aim of this…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].